Alpha 2.0
Login Register
» Authors » Eric D Hsi

Eric D Hsi

Explore the profile of Eric D Hsi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 317
Citations 8201
Followers 0
Related Specialties
Hematology
Pathology
Oncology
Top 10 Co-Authors
Ken H Young
Attilio Orazi
Miguel A Piris
Govind Bhagat
Michael B Moller
Carlo Visco
Zijun Y Xu-Monette
Jane N Winter
L Jeffrey Medeiros
Karen Dybkaer
Published In
Blood
Am J Clin Pathol
Mod Pathol
Leuk Lymphoma
Am J Surg Pathol
Affiliations
Soon will be listed here.
Recent Articles
1.
Angioimmunoblastic T-cell lymphoma: Characterization of clonal T and B cells and a patient-derived xenograft study of coexisting T- and B-cell proliferation
Zhao X, Jagadeesh D, Bodo J, Durkin L, Lindner D, Ondrejka S, et al.
EJHaem . 2025 Jan; 6(1):e1080. PMID: 39877932
Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma with a poor prognosis. AITL is associated with Epstein-Barr virus (EBV)-positive B cells in most cases, suggesting a possible...
2.
Acute Leukemias of Ambiguous Lineage With MDS-Associated Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With MDS-Associated Mutations: A Study From the Bone Marrow Pathology Group
Kirtek T, Chen W, Harris J, Bagg A, Foucar K, Tam W, et al.
Am J Hematol . 2024 Nov; 100(2):300-304. PMID: 39578955
No abstract available.
3.
Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors
Morrow W, Milligan N, Ohgami R, Young K, Wang B, Vega F, et al.
J Hematop . 2024 Nov; 17(4):215-222. PMID: 39549220
Anaplastic large cell lymphoma with primary presentation in, and disease limited to, the central nervous system (primary CNS ALCL) is a rare and aggressive lymphoma found in a sensitive anatomic...
4.
High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy
Han J, McCall C, Isom S, Smith W, Begley S, Jenneman D, et al.
Leuk Lymphoma . 2024 Oct; 66(2):325-328. PMID: 39411845
No abstract available.
5.
Closing the gap between biology and classification in splenic B-cell lymphomas
Blombery P, de Jong D, Ferry J, Hsi E, Ondrejka S, Seymour J, et al.
Histopathology . 2024 Oct; 86(1):69-78. PMID: 39403047
The mature splenic B-cell lymphomas are an enigmatic group of lymphoid neoplasms that have long caused significant difficulty for the practicing pathologist due to overlapping diagnostic features among entities and...
6.
Correction: Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification
Ferry J, Hill B, Hsi E
J Hematol Oncol . 2024 Aug; 17(1):75. PMID: 39198876
No abstract available.
7.
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma
Xu-Monette Z, Luo C, Yu L, Li Y, Bhagat G, Tzankov A, et al.
Oncoimmunology . 2024 Aug; 13(1):2384667. PMID: 39108501
Deficient (d) DNA mismatch repair (MMR) is a biomarker predictive of better response to PD-1 blockade immunotherapy in solid tumors. dMMR can be caused by mutations in MMR genes or...
8.
Expression of CD6 in Aggressive NK/T-cell Neoplasms and Assessment as a Potential Therapeutic Target: A Bone Marrow Pathology Group Study
Zhao X, McCall C, Block J, Ondrejka S, Thakral B, Wang S, et al.
Clin Lymphoma Myeloma Leuk . 2024 Aug; 24(11):e808-e818. PMID: 39089930
Background: Aggressive NK/T-Cell neoplasms are rare hematological malignancies characterized by the abnormal proliferation of NK or NK-like T (NK/T) cells. CD6 is a transmembrane signal transducing receptor involved in lymphocyte...
9.
Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification
Ferry J, Hill B, Hsi E
J Hematol Oncol . 2024 Jul; 17(1):51. PMID: 38978094
In 2022, two updated classification systems for lymphoid neoplasms were published by the World Health Organization (WHO Classification of Haematolymphoid Tumours, 5th edition, referred to hereafter as WHO-HAEM5) and the...
10.
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL
Smith M, Jegede O, Martin P, Till B, Parekh S, Yang D, et al.
Blood . 2024 May; 144(10):1083-1092. PMID: 38820500
Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus,...